Literature DB >> 28467579

Primary small intestinal non-Hodgkin lymphoma diagnosed after emergency surgery.

Tevfik Avcı1, Hakan Yabanoğlu, İlker Murat Arer, Nazım Emrah Koçer, Kenan Çalışkan, Pelin Börcek, Yahya Ekici.   

Abstract

BACKGROUND: The aim of this study was to investigate clinical manifestation, diagnosis, treatment, and prognosis of patients with primary gastrointestinal non-Hodgkin lymphoma (PGI NHL), whose initial presentation was bowel obstruction or perforation.
METHODS: Data of patients who underwent surgical intervention due to radiological evidence of perforation or intestinal obstruction and were subsequently diagnosed with intestinal lymphoma at Baskent University hospitals between January 2007 and November 2014 were examined retrospectively. Medical records, clinical history, symptoms, pathological reports, and treatment modalities were analyzed.
RESULTS: Study population comprised 17 patients (8 male, 9 female) with PGI NHL and mean age of 52±20.2 years. Symptoms reported by the patients were abdominal pain, nausea, vomiting, weight loss, and loss of appetite. All 17 patients underwent surgical treatment; 12 also received postoperative chemotherapy. Most common pathological subtype was diffuse large B-cell lymphoma (70.5%). Mean follow-up time was 26 months (range: 1-69 months) and 5-year survival rate was 64.3%.
CONCLUSION: Initial presentation of PGI NHL may be obstruction with or without perforation; clinicians and surgeons should keep this in mind while assessing patient with bowel obstruction, and particularly patient in fifth decade of life.

Entities:  

Mesh:

Year:  2017        PMID: 28467579     DOI: 10.5505/tjtes.2016.02359

Source DB:  PubMed          Journal:  Ulus Travma Acil Cerrahi Derg


  1 in total

1.  Small bowel lymphoma presenting as inguinal hernia: case report and literature review.

Authors:  Michele Teodoro; Maurizio Mannino; Marco Vitale; Edoardo Mattone; Valentina Palumbo; Filippo Fraggetta; Adriana Toro; Isidoro Di Carlo
Journal:  World J Surg Oncol       Date:  2018-05-15       Impact factor: 2.754

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.